Current and potential treatments of Parkinson's disease

doi:10.1017/CBO9780511544873.043

42 - Current and potential treatments of Parkinson's disease

from Part VII - Parkinson's and related movement disorders

Published online by Cambridge University Press: 04 August 2010

Anthony E. Lang and

M. Flint Beal: Affiliation:
Cornell University, New York
Anthony E. Lang: Affiliation:
University of Toronto
Albert C. Ludolph: Affiliation:
Universität Ulm, Germany
Clifford W. Shults: Affiliation:
Department of Neurosciences, University of California, La Jolla, San Diego, CA, USA and VA San Diego Healthcare System, Dan Diego, CA, USA

Book contents

Get access

Summary

Parkinson's disease (PD) is a progressive, degenerative neurological disorder characterized by rest tremor, bradykinesia, cogwheel rigidity and postural instability (Lang & Lozano, 1998). In the later stages of the illness approximately 30–40% of patients will develop cognitive compromise. The cardinal pathological features of PD are loss of neurons on the substantia nigra pars compacta (SNpc) and the presence of eosinophilic, intracytoplasmic inclusions, and Lewy bodies (Braak & Braak, 2000). The neurons of the SNpc project primarily to the caudate and putamen, which are referred to collectively as the striatum, and utilize the neurotransmitter dopamine. Dopamine is severely reduced in the SNpc and striatum in parkinsonian brains (Hornykiewicz, 2002). Although the loss of neurons is most conspicuous in the SNpc, neuronal loss and Lewy bodies are found in a number of brain regions, e.g. locus ceruleus, entorhinal region and amygdala (Braak & Braak, 2000). The neuronal loss and the presence of Lewy bodies in regions other than the SNpc suggest that although treatments that target only the nigrostriatal dopaminergic system may substantially benefit patients, they are unlikely to completely resolve the deficits of PD.

The following review presents a strategic framework through which to consider targets for therapies of PD. In some of the areas we are just beginning to have treatments, e.g. slowing the progression of the disease, and in others we have well-established therapies, e.g. augmentation of the function of the remaining dopaminergic system.

Type: Chapter
Information: Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 612 - 622

DOI: https://doi.org/10.1017/CBO9780511544873.043 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Aarsland, D., Laake, K., Larsen, J. P. & Janvin, C. (2002). Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol., Neurosurg. Psychiatr., 72, 708–12CrossRef Google Scholar PubMed

Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sorensen, P. (2003). Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol., 60, 387–92CrossRef Google Scholar

Adler, C. H., Singer, C., O'Brien, C. et al. (1998). Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopacarbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol., 55, 1089–95CrossRef Google Scholar

Alam, Z. I., Daniel, S. E., Lees, A. J.et al. (1997). A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochemi., 69 (3), 1326–9CrossRef Google Scholar

Andersen, J. K. (2001). Does neuronal loss in Parkinson's disease involve programmed cell death?Bioessays, 23 (7), 640–6CrossRef Google Scholar PubMed

Barone, P., Bravi, D., Bermejo-Pareja, F.et al. (1999). Pergolide monotherapy in the treatment of early PD. A randomized controlled study. Neurology, 53, 573–9CrossRef Google Scholar PubMed

Beal, M. F. (2002). Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med., 32 (9), 797–803CrossRef Google Scholar PubMed

Björklund, A. (2000). Cell replacement strategies for neurodegenerative disorders. Novartis Foundation Symposium, 231, 7–15; discussion 16–20Google Scholar PubMed

Braak, H. & Braak, E. (2000). Pathoanatomy of Parkinson's disease. J. Neurol.) 247 (2), II3–10Google Scholar PubMed

Brooks, D. J., Abbott, R. J., Lees, A. J.et al. (1998). A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin. Neuropharmacol., 21, 101–7Google Scholar PubMed

Burchiel, K. J., Anderson, V. C., Favre, J.et al. (1999). Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery, 45 (6), 1375–82CrossRef Google Scholar PubMed

Butzer, J. F., Silver, D. E. & Sans, A. L. (1975). Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology, 25, 603–6Google Scholar PubMed

Calne, D. B., Techenne, P. F., Claveria, L. E.et al. (1974). Bromocriptine in Parkinsonism. Br. Med. J., 4, 442–4CrossRef Google Scholar PubMed

Cantello, R., Riccio, A., Gilli, M.et al. (1986). Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital. J. Neurol. Sci., 7, 139–43CrossRef Google Scholar

Chung, K. K., Dawson, V. L. & Dawson, T. M. (2001). The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci., 24 (11 Suppl), S7–14CrossRef Google Scholar PubMed

Cotzias, G. C., Papavasiliou, P. S. & Gellene, R. (1969). Modification of Parkinsonism-chronic treatment with L-dopa. N. Engl. J. Med., 280, 337–45CrossRef Google Scholar PubMed

Bie, R. M., Haan, R. J., Nijssen, P. C.et al. (1999). Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. Lancet, 354 (9191), 1665–9CrossRef Google Scholar PubMed

Bie, R. M., Haan, R. J., Schuurman, P. R.et al. (2002). Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review. Neurology, 58 (7), 1008–12CrossRef Google Scholar PubMed

Dexter, D. T., Carter, C. J., Wells, F. R.et al. (1989). Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 52 (2), 381–9CrossRef Google Scholar PubMed

Drukarch, B. & Muiswinkel, F. L. (2000). Drug treatment of Parkinson's disease. Time for phase II. Biochem. Pharmacol., 59 (9), 1023–31CrossRef Google Scholar PubMed

Du, Y., Ma, Z., Lin, S.et al. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 98 (25), 14669–74CrossRef Google Scholar PubMed

Dupont, E., Anderson, A., Boqs, J.et al. (1996). Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol. Scand., 93, 14–20CrossRef Google Scholar PubMed

Eberling, J. L., Pivirotto, P., Bringas, J.et al. (2002). The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp. Neurol., 178 (2), 236–42CrossRef Google Scholar

Etminan, M., Samii, A., Takkouche, B.et al. (2001). Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Safety, 24 (11), 863–8CrossRef Google Scholar PubMed

Freed, C. R., Greene, P. E., Breeze, R. E.et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New Engl. J. Med., 344 (10), 710–19CrossRef Google Scholar PubMed

Furukawa, Y., Vigouroux, S., Wong, H.et al. (2002). Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann. Neurol., 51 (6), 779–82CrossRef Google Scholar PubMed

Galvin, J. E., Lee, V. M., Schmidt, M. L.et al. (1999). Pathobiology of the Lewy body. Adv. Neurol., 80, 313–24Google Scholar PubMed

Giasson, B. I. & Lee, V. M. (2001). Parkin and the molecular pathways of Parkinson's disease. Neuron, 31 (6), 885–8CrossRef Google Scholar PubMed

Giasson, B. I., Duda, J. E., Murray, I. V.et al. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290 (5493), 985–9CrossRef Google Scholar PubMed

Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 9 (5), 589–95CrossRef Google Scholar PubMed

Goetz, C. G., Blasucci, L. M., Leurgans, S. & Pappert, E. J. (2000). Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology, 55, 789–94CrossRef Google Scholar PubMed

Gold, B. G. & Nutt, J. G. (2002). Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr. Opin. Pharmacol., 2 (1), 82–6CrossRef Google Scholar PubMed

Guttman, M. and the International Pramipexole-Bromocriptine Study Group (1997). Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology, 49, 1060–5CrossRef Google Scholar PubMed

Haas, R. H., Nasirian, F., Nakano, K., Ward, D.et al. (1995). Low platelet mitochondrial Complex I and Complex II/III activity in early untreated Parkinson's disease. Ann. Neurol., 37, 714–22CrossRef Google Scholar PubMed

Hallett, M. & Litvan, I. (1999). Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. Neurology, 53 (9), 1910–21CrossRef Google Scholar PubMed

Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging, 18 (9), 685–716CrossRef Google Scholar PubMed

Hely, M. A., Morris, J. G. L. & Reid, W. G. J. (1994). The Sydney multicentre study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J. Neurol., Neurosurg., Psychiatr., 57, 903–10CrossRef Google Scholar PubMed

Hirsch, E.., Hunot, S., Damier, P.et al. (1998). Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?Ann. Neurol., 44 (3 Suppl 1), S115–20CrossRef Google Scholar PubMed

Hornykiewicz, O. (2002). Dopamine miracle: from brain homogenate to dopamine replacement. Movement Disord., 17 (3), 501–8CrossRef Google Scholar PubMed

Hutton, J. T., Morris, J. L., Bush, D. F.et al. (1989). Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology, 39, 67–72Google Scholar

Isacson, O. (2002). Models of repair mechanisms for future treatment modalities of Parkinson's disease. Brain Res. Bull., 57 (6), 839–46CrossRef Google Scholar PubMed

Kingsbury, A. E., Mardsen, C. D. & Foster, O. J. (1998). DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?Movement Disord., 13 (6), 877–84CrossRef Google Scholar PubMed

Kitada, T., Asakawa, S., Hattori, N.et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605–8CrossRef Google Scholar

Koller, W. C., Hutton, J. T., Tolosa, E.et al. (1999). Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology, 53, 1012–19CrossRef Google Scholar PubMed

Kordower, J. H., Palfi, S., Chen, E. Y.et al. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol., 46 (3), 419–243.0.CO;2-Q>CrossRef Google Scholar

Kordower, J. H., Emborg, M. E., Bloch, J.et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290 (5492), 767–73CrossRef Google Scholar

Kumar, S., Bhatia, M. & Behari, M. (2002). Sleep disorders in Parkinson's disease. Movement Disord., 17 (4), 775–81CrossRef Google Scholar PubMed

Laitinen, L. V., Bergenheim, A. T. & Hariz, M. I. (1992). Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J. Neurosurg., 76 (1), 53–61CrossRef Google Scholar PubMed

Lang, A. E. (2000). Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch. Neurol., 57 (8), 1118–25CrossRef Google Scholar PubMed

Lang, A. E. & Lozano, A. M. (1998). Parkinson's disease. First of two parts. N. Engl. J. Med., 339 (15), 1044–53CrossRef Google Scholar PubMed

Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. (1983). Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979–80CrossRef Google Scholar PubMed

Langston, J. W., Forno, L. S., Tetrud, J.et al. (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 46 (4), 598–6053.0.CO;2-F>CrossRef Google Scholar PubMed

Lieberman, A., Ranhosky, A. & Korts, D. (1997). Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo controlled, parallel-group study. Neurology, 49, 162–8CrossRef Google Scholar PubMed

Limousin, P., Krack, P., Pollak, P.et al. (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med., 339 (16), 1105–11CrossRef Google Scholar PubMed

Lindvall, O. & Hagell, P. (2001). Cell therapy and transplantation in Parkinson's disease. Clin. Chem. Laborat. Med., 39 (4), 356–61Google Scholar PubMed

Luginger, E., Wenning, G. K., Bosch, S. & Poewe, W. (2000). Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Movement Disord., 15, 873–83.0.CO;2-I>CrossRef Google Scholar PubMed

Matthews, R. T., Klivenyi, P., Mueller, G.et al. (1999). Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol., 157 (1), 120–6CrossRef Google Scholar PubMed

McGeer, E. G. & McGeer, P. L. (1997). The role of the immune system in neurodegenerative disorders. Movement Disord., 12 (6), 855–8CrossRef Google Scholar PubMed

McNaught, K. S., Olanow, C. W., Halliwell, B.et al. (2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci., 2 (8), 589–94CrossRef Google Scholar PubMed

Mizuno, Y., Hattori, N., Mori, H.et al. (2001). Parkin and Parkinson's disease. Curr. Opin. Neurol., 14 (4), 477–82CrossRef Google Scholar PubMed

Montastruc, J. L., Rascol, O., Senard, J. M. & Rascol, A. (1994). A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J. Neurol., Neurosurg. Psychiatr., 57, 1034–8CrossRef Google Scholar PubMed

Nijhawan, D., Honarpour, N. & Wang, X. (2000). Apoptosis in neural development and disease. Ann. Rev. Neurosci., 23, 73–87CrossRef Google Scholar PubMed

Nutt, J. G., Burchiel, K. J., Comella, C. L.et al. and ICV GDNF Study Group (2003). Implanted intracerebroventricular glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 60, 69–73CrossRef Google Scholar PubMed

Oh, M. Y., Abosch, A., Kim, S. H.et al. (2002). Long-term hardware-related complications of deep brain stimulation. Neurosurgery, 50 (6), 1268–74; discussion 1274–6Google Scholar PubMed

Olanow, C. W., Fahn, S., Muenter, M.et al. (1994). A muticenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Movement Disord., 9, 40–7CrossRef Google Scholar

Olanow, C. W., Hauser, R. A., Gauger, L.et al. (1995). The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol., 38, 771–7CrossRef Google Scholar PubMed

Olanow, C. W., Goetz, C. G., Kordower, J. H.et al. (2003). A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol., 54, 403–14CrossRef Google Scholar

Pålhagen, S., Heinonan, E. H., Hagglund, J.et al. (1998). Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology, 51, 520–5CrossRef Google Scholar PubMed

Parkinson Disease Research Group in the United Kingdom (1993). Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three-year interim report. Br. Med. J., 307, 469–72CrossRef

Parkinson Study Group. (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med., 328, 176–83CrossRef

Parkinson Study Group. (1997a). Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. J. Am. Med. Assoc., 278 (2), 125–30CrossRef

Parkinson Study Group. (1997b). Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol., 42 (5), 747–55CrossRef

Parkinson Study Group. (1999). Low-dose clozapine for the treatment of drug-induced psychoses in Parkinson's disease. N. Engl. J. Med., 340, 757–63CrossRef

Parkinson Study Group. (2000). Pramipexole vs. levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. J. Am. Med. Assoc., 284, 1931–8CrossRef

Polymeropoulos, M. H., Lavedan, C., Leroy, E.et al. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045–7CrossRef Google Scholar PubMed

Przedborski, S. & Jackson-Lewis, V. (1998). Mechanisms of MPTP toxicity. Movement Disord., 13 Suppl 1, 35–8Google Scholar PubMed

Rajput, A. H., Martin, W., Saint-Hilaire, M. H.et al. (1997). Tolcapone improves motor function in Parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology, 49, 1066–71CrossRef Google Scholar PubMed

Rascol, O., Brooks, D. J., Korczyn, A. D.et al. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med., 342, 1484–91CrossRef Google Scholar PubMed

Reed, J. C. (2002). Apoptosis-based therapies. Nat. Rev. Drug Discover., 1 (2), 111–21CrossRef Google Scholar PubMed

Rinne, U. K., Larsen, J. P., Siden, A.et al. (1998). Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology, 51, 1309–14CrossRef Google Scholar PubMed

Riopelle, R. J. (1987). Bromocriptine and the clinical spectrum of Parkinson's disease. Can. J. Neurol. Sci., 14, 455–9CrossRef Google Scholar PubMed

Sanchez-Ramos, J. R., Övervik, E. & Ames, B. N. (1994). A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration, 3, 197–204Google Scholar

Schapira, A. H. V., Mann, V. M., Cooper, J. M.et al. (1990). Anatomic disease specificity of NADH CoQ1 reductase complex I deficiency in Parkinson's disease. J. Neurochem., 55, 2142–5CrossRef Google Scholar PubMed

Schuurman, P. R., Bosch, D. A., Bossuyt, P. M.et al. (2000). A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N. Engl. J. Med., 342 (7), 461–8CrossRef Google Scholar PubMed

Schwab, R. S., England, A. C. Jr., Poskancer, D. C.et al. (1969). Amantadine in the treatment of Parkinson's disease. J. Am. Med. Assoc., 208, 1168–70CrossRef Google Scholar PubMed

Shimura, H., Hattori, N., Kubo,, S.et al. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 25, 302–5CrossRef Google Scholar

Shults, C. W. (1998). Neurotrophic factors in neurodegenerative disorder. In Parkinson's Disease and Movement Disorders, ed. J. Jankovic and E. Tolosa, pp. 105–18. 3rd edn. Williams and Wilkins

Shults, C. W., Haas, R. H., Passov, D. & Beal, M. F. (1997). Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol., 42, 261–4CrossRef Google Scholar

Shults, C. W., Oakes, D., Kieburtz, K.et al. (2002). Effects of coenzyme Q10 in early Parkinson disease-Evidence of slowing of the functional decline. Arch. Neurol., 59, 1541–50CrossRef Google Scholar PubMed

Sian, J., Dexter, D. T., Lees, A. J.et al. (1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol., 36 (3), 348–55CrossRef Google Scholar PubMed

Snow, B. J., MacDonald, L., Mcauley, D.et al. (2000). The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin. Neuropharmacol., 23, 82–5CrossRef Google Scholar PubMed

Spillantini, M. G., Schmidt, M. L., Lee, V. M.et al. (1997). Alpha-synuclein in Lewy bodies. Nature, 388 (6645), 839–40CrossRef Google Scholar PubMed

Takeda, A., Mallory, M., Sundsmo, M.et al. (1998). Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol., 152 (2), 367–72Google Scholar PubMed

Tan, E. K., Lum, S. Y., Fook-Chong, S. M.et al. (2002). Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology, 58 (3), 465–8CrossRef Google Scholar PubMed

Tarnopolsky, M. A. & Beal, M. F. (2001). Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol., 49 (5), 561–74CrossRef Google Scholar PubMed

Teismann, P. & Ferger, B. (2001). Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse, 39 (2), 167–743.0.CO;2-U>CrossRef Google Scholar PubMed

The Deep-Brain Stimulation for Parkinson's Disease Study Group (2001). Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N. Engl. J. Med., 345, 956–63CrossRef

The Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med., 1340, 757–63

Trepanier, L. L., Kumar, R., Lozano, A. M.et al. (2000). Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. Brain Cogn., 42 (3), 324–47CrossRef Google Scholar PubMed

Verhagen Metman, L. V., Del Dotto, P., LePoole, K.et al. (1999). Amantadine for levodopa-induced dyskinesias. A 1-year follow-up study. Arch. Neurol., 56, 1383–6CrossRef Google Scholar

Wakabayashi, K., Matsumoto, K., Takayama, K.et al. (1997). NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett., 239 (1), 45–8CrossRef Google Scholar PubMed

Wermuth, L. and the Danish Pramipexole Study Group (1998). A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur. J. Neurol., 5, 235–44CrossRef Google Scholar PubMed

Wolters, E. C., Tesselaar, H. J. M. and the International (NL and UK) Sinemet CR Study Group (1996). International (NL–UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J. Neurol., 243, 235–40CrossRef Google Scholar PubMed

Wu, D. C., Jackson-Lewis, V., Vila, M.et al. (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 22 (5), 1763–71CrossRef Google Scholar PubMed

Zhang, C., Steiner, J. P., Hamilton, G. S.et al. (2001). Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J. Neurosci., 21 (15), RC156CrossRef Google Scholar PubMed

Zimmermann, K. C., Bonzon, C. & Green, D. R. (2001). The machinery of programmed cell death. Pharmacol. Therap., 92 (1), 57–70CrossRef Google Scholar PubMed